252 related articles for article (PubMed ID: 8616876)
1. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.
Westra WH; Baas IO; Hruban RH; Askin FB; Wilson K; Offerhaus GJ; Slebos RJ
Cancer Res; 1996 May; 56(9):2224-8. PubMed ID: 8616876
[TBL] [Abstract][Full Text] [Related]
2. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung.
Cooper CA; Carby FA; Bubb VJ; Lamb D; Kerr KM; Wyllie AH
J Pathol; 1997 Apr; 181(4):401-4. PubMed ID: 9196437
[TBL] [Abstract][Full Text] [Related]
3. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
[TBL] [Abstract][Full Text] [Related]
4. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
5. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
[TBL] [Abstract][Full Text] [Related]
6. p53 alterations in atypical alveolar hyperplasia of the human lung.
Slebos RJ; Baas IO; Clement MJ; Offerhaus GJ; Askin FB; Hruban RH; Westra WH
Hum Pathol; 1998 Aug; 29(8):801-8. PubMed ID: 9712420
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.
Yoshida Y; Shibata T; Kokubu A; Tsuta K; Matsuno Y; Kanai Y; Asamura H; Tsuchiya R; Hirohashi S
Lung Cancer; 2005 Oct; 50(1):1-8. PubMed ID: 15950315
[TBL] [Abstract][Full Text] [Related]
8. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
[TBL] [Abstract][Full Text] [Related]
9. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.
Rodenhuis S; Slebos RJ; Boot AJ; Evers SG; Mooi WJ; Wagenaar SS; van Bodegom PC; Bos JL
Cancer Res; 1988 Oct; 48(20):5738-41. PubMed ID: 3048648
[TBL] [Abstract][Full Text] [Related]
10. Detection of codon 12 K-ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas.
Urban T; Ricci S; Danel C; Antoine M; Kambouchner M; Godard V; Lacave R; Bernaudin JF
Br J Cancer; 2000 Jan; 82(2):412-7. PubMed ID: 10646897
[TBL] [Abstract][Full Text] [Related]
11. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
[TBL] [Abstract][Full Text] [Related]
13. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.
Cerny WL; Mangold KA; Scarpelli DG
Cancer Res; 1992 Aug; 52(16):4507-13. PubMed ID: 1643642
[TBL] [Abstract][Full Text] [Related]
14. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma.
Mills NE; Fishman CL; Rom WN; Dubin N; Jacobson DR
Cancer Res; 1995 Apr; 55(7):1444-7. PubMed ID: 7882350
[TBL] [Abstract][Full Text] [Related]
15. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application].
Zhang G; Sun Y; Wang M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung.
Licchesi JD; Westra WH; Hooker CM; Herman JG
Clin Cancer Res; 2008 May; 14(9):2570-8. PubMed ID: 18451218
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients.
Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A
Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679
[TBL] [Abstract][Full Text] [Related]
18. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.
Rusch VW; Reuter VE; Kris MG; Kurie J; Miller WH; Nanus DM; Albino AP; Dmitrovsky E
J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1465-9. PubMed ID: 1331621
[TBL] [Abstract][Full Text] [Related]
19. Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung.
Morandi L; Asioli S; Cavazza A; Pession A; Damiani S
Lung Cancer; 2007 Apr; 56(1):35-42. PubMed ID: 17241687
[TBL] [Abstract][Full Text] [Related]
20. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
